Year: 2019
Type: article
Abstract: Efficacy of lenalidomide in high-risk diffuse large B-cell lymphoma *Median age at the time of lenalidomide initiation.† Patients unable to achieve a complete response with upfront therapy.‡ Groups not statistically different, apart from the number of patients receiving rituximab in the transformed follicular lymphoma group, P = 0Á045.
Source: British Journal of Haematology
DOI: 10.1111/bjh.16302
Institutions: University of Rochester Medicine, University of Rochester
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2995780448